We are live on
!
Find out more
VCG
Vantage Consulting Group Portfolio holdings
AUM
$19.7M
1-Year Est. Return
280.87%
This Fund
S&P 500
This Quarter
Est. Return
+17.65%
1 Year Est. Return
+280.87%
3 Year Est. Return
+261.08%
5 Year Est. Return
+180.34%
10 Year Est. Return
–
AUM
$1.23B
AUM Growth
–
Cap. Flow
+$1.06B
Cap. Flow
% of AUM
86.51%
Top 10 Holdings %
Top 10 Hldgs %
94.5%
Holding
1,884
New
1,883
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$911M |
| 2 |
ADC Therapeutics
ADCT
|
+$55.1M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$25.5M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.96M |
| 5 |
Kroger
KR
|
+$366K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.04% |
| 2 | Technology | 0.89% |
| 3 | Consumer Discretionary | 0.79% |
| 4 | Industrials | 0.61% |
| 5 | Consumer Staples | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
G-III Apparel Group
GIII
$1.54B
| $26K | ﹤0.01% |
+1,091
| New | +$20.3K |
|
752
Huntington Bancshares
HBAN
$35.1B
| $26K | ﹤0.01% |
+2,035
| New | +$23.1K |
|
753
Iron Mountain
IRM
$36.9B
| $26K | ﹤0.01% |
+876
| New | +$24.3K |
|
754
Jabil
JBL
$33.4B
| $26K | ﹤0.01% |
+619
| New | +$23.4K |
|
755
Lindsay Corp
LNN
$1.15B
| $26K | ﹤0.01% |
+200
| New | +$22.8K |
|
756
Medtronic
MDT
$111B
| $26K | ﹤0.01% |
+221
| New | +$24.3K |
|
757
M&T Bank
MTB
$36.2B
| $26K | ﹤0.01% |
+208
| New | +$23.7K |
|
758
Nu Skin
NUS
$251M
| $26K | ﹤0.01% |
+474
| New | +$24.9K |
|
759
PRA Group
PRAA
$666M
| $26K | ﹤0.01% |
+655
| New | +$26K |
|
760
RadNet
RDNT
$5.25B
| $26K | ﹤0.01% |
+1,323
| New | +$23.4K |
|
761
Regis Corp
RGS
$68.7M
| $26K | ﹤0.01% |
+140
| New | +$21.3K |
|
762
State Street SPDR Portfolio TIPS ETF
SPIP
$999M
| $26K | ﹤0.01% |
+835
| New | +$25.7K |
|
763
Supernus Pharmaceuticals
SUPN
$2.67B
| $26K | ﹤0.01% |
+1,014
| New | +$21.8K |
|
764
Teleflex
TFX
$6.18B
| $26K | ﹤0.01% |
+63
| New | +$23.2K |
|
765
Gentherm
THRM
$1.28B
| $26K | ﹤0.01% |
+391
| New | +$21.1K |
|
766
West Pharmaceutical
WST
$24.5B
| $26K | ﹤0.01% |
+91
| New | +$25.5K |
|
|
PXD
767
DELISTED
Pioneer Natural Resource Co.
PXD
| $26K | ﹤0.01% |
+230
| New | +$22.4K |
|
|
HIBB
768
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $26K | ﹤0.01% |
+573
| New | +$25.6K |
|
769
Coty
COTY
$2.46B
| $25K | ﹤0.01% |
+3,500
| New | +$18K |
|
770
3D Systems Corp
DDD
$462M
| $25K | ﹤0.01% |
+2,399
| New | +$19.5K |
|
771
EOG Resources
EOG
$77.6B
| $25K | ﹤0.01% |
+500
| New | +$21.7K |
|
772
Fidelity National Information Services
FIS
$23.1B
| $25K | ﹤0.01% |
+180
| New | +$25.7K |
|
773
The Greenbrier Companies
GBX
$1.54B
| $25K | ﹤0.01% |
+680
| New | +$22.4K |
|
774
Global Payments
GPN
$23.6B
| $25K | ﹤0.01% |
+114
| New | +$21.3K |
|
|
HES
775
DELISTED
Hess
HES
| $25K | ﹤0.01% |
+472
| New | +$21.5K |
|
Similar funds
MVG
NCM
FFGIM
PIM
HFG
SWM
ICM
SM
Vantage Consulting Group's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Vantage Consulting Group, which disclosed 1,884 positions worth $1.23B. Its ten largest holdings account for 94% of the portfolio.
Its largest position is Royalty Pharma: 21,477,282 shares worth $1.07B.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Technology and Consumer Discretionary.
- Vantage Consulting Group's largest Q4 2020 buy was Royalty Pharma: 21,477,282 shares worth $1.07B.
- Vantage Consulting Group's ten largest holdings make up 94% of its $1.23B portfolio in Q4 2020.
- Vantage Consulting Group disclosed 1,884 positions in Q4 2020, its first 13F filing on record.
Based on Vantage Consulting Group's 13F filing for Q4 2020, filed 12 Feb 2021.